摘要
胃癌发病率最高的地区集中在东南亚和中国。手术是目前唯一可能治愈胃癌的手段,但近2/3的患者确诊时已是进展期,术后复发和转移率较高,5年生存率不足50%。术后辅助化疗是改善患者远期生存的主要方法,大量研究显示Ⅲ期胃癌术后辅助化疗可以明显提高患者的生存率,
出处
《医学临床研究》
CAS
2013年第4期788-790,共3页
Journal of Clinical Research
参考文献18
-
1Herszenyi L, Tulassay Z. Epidemiology of gastrointestinaland liver tumors[J]. Eur Rev Med Pharmacol Sci ,2010,14(4):249-258.
-
2Brenner H. Epidemiology of stomach cancer[J]. Methods MolBiol ,2009,472(4): 467-477.
-
3Zhao SL, Fang JY. The role of postoperative adjuvant chem-otherapy following curative resection for gastric cancer: ameta_analysis[J]. Cancer Invest .2008; 26(3):317-325.
-
4Macdonald JS. Role of post-operative chemoradiation in resec-ted gastric cancer[J]. J Surg Oncol ,2005,90(3) : 166-167.
-
5GASTRIC (Global Advanced/Adjuvant Stomach Tumor Re-search International Collaboration) Group, Benefit of adju-vant chemotherapy for resectable gastric cancer: a meta-anal-ysis[J]. JAMA ,2010,303(17) = 1729-1733.
-
6Petrovic Z, Tarabar D, Doder R, et al . Oxaliplatin (L-OHP)and capecitabine (X) as second-line chemotherapy in patientswith advanced gastric cancer (abstract 1199)[J]. Proc AmSoc Clin Oncol ,2003,22(1) : 29.
-
7Park YH, Kim B-S, Ryoo B-Y . Oxaliplatin and capecitabinecombination chemotherapy for patients with advanced gastriccarcinoma: a pilot study results (abstract 57)[J]. Presentedat the second annual American Society of Clinical OncologyGastrointestinal Cancers Symposium, Miami, Florida ,2005:27-29.
-
8Park YH, Kim BS, Ryoo BY,et al . h phase H study ofcapecitabine plus 3-weekly oxaliplatin as first-line therapy forpatients with advanced gastric cancer [ J]. Br J Cancer,. 2006,94C7):959-963.
-
9Sumpter K, Harper-Wynne C, Cunningham et al . Reportof two protocol planned interim analyses in a randomisedmulticentre phase 瓜 study comparing capecitabine with flu-orouracil and oxaliplatin with cisplatin in patients with ad-vanced oesophagogastric cancer receiving ECF [ J ]. Br JCancer,2005,92(11) : 1976-1983.
-
10Bang YJ,Kim YW, Yang HK, et al . Adjuvant capecitabineand oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC) : a phase 3 open-label, randomised controlledtrial[J]. Lancet ,2012,379(9813):315-321.
同被引文献20
-
1Gravalos C Jimeno. A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target [ J]. Ann Oncol, 2008,19 (9) :1523-1529.
-
2Chauhan SC, Vannatta K, Ebeling MC, et al. Expression and functions of transmembrane mucin MUC13 in ovarian cancer [ J 1. Cancer Res ,2009,69 ( 3 ) :765-774.
-
3Bilous M, Osamura RY, Ruschoff J, et al. HER-2 amplification is highly homogenous in gastric cancer[ j]. Hum Pathol,2010,41 (2) :304-305.
-
4Jorgensen Jr. Targeted HER2 Treatment in Advanced Gastric Cancer[J]. Oneology, 2010, 78(1): 26-33.
-
5Park DI, Yun JW, Park JH, et al. HER-2/neu amplification is an independent prognostic factor in gastrieeancer [ J ]. Dig Dis Sci, 2006,51 (8) :1371-1379.
-
6Ruschoff J, Nagelmeier I, Baretton G, et al. Her2 testing in gas- tric cancer. What is different in comparison to breast cancer[ J]. Der Pathologe, 2010,31 (3) :208-217.
-
7Tanner M, Hollmen M, Junttila TI?, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase Ilalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab [ J ]. Ann Oncol, 2005,16 ( 2 ) : 273- 278.
-
8Grabseh H, Sivakumar S, Gray S,et al. HER2 expression in gas- tric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series [ J ]. Cell Oncol, 2010,32(1-2) :57-65.
-
9Kim, Hwang Phil1, Kim, et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification syner- gistically with cisplatin[ J]. Int J 0ncol,2008,32( 1 ) :89-95.
-
10宋岩,黄镜,王金万.HER2/neu基因扩增和蛋白表达与晚期胃癌患者预后的关系[J].癌症,2010,29(1):76-81. 被引量:25
-
1安继荣,刘小辉,成建荣.参芪扶正注射液配合胃癌术后辅助化疗临床观察[J].西部中医药,2015,28(8):125-127. 被引量:3
-
2杨林,王金万,陈平.可切除胃癌术后辅助化疗现状[J].癌症进展,2005,3(1):55-58. 被引量:6
-
3张金林,朱培森.胃癌术后辅助化疗对生存率的影响[J].癌症,1997,16(6):449-450. 被引量:1
-
4张占东,孔烨,马飞,刘洪兴,张斌,黄晋熙,马二民,花亚伟.奥沙利铂联合S-1与XELOX方案在胃癌术后辅助化疗中的临床效果比较[J].中国普通外科杂志,2013,22(6):747-751. 被引量:3
-
5尚春迎.奥沙利铂联合S-1与XELOX方案在胃癌术后辅助化疗中的临床效果比较[J].中国医药指南,2015,13(33):151-152. 被引量:4
-
6张晓飞,杨康,苏先旭.奥沙利铂联合替吉奥在胃癌术后辅助化疗中的研究[J].重庆医学,2013,42(26):3107-3109. 被引量:13
-
7胡泽成,赵晓春,伍小平,樊善继.紫杉醇脂质体联合替吉奥与XELOX在胃癌术后辅助化疗中的对比研究[J].中国全科医学,2015,18(13):1545-1548. 被引量:22
-
8黄露迷,冀晓辉,王春梅,王东林,李代蓉.替吉奥单药与替吉奥联合奥沙利铂在胃癌术后辅助化疗中的临床疗效观察[J].中国医药指南,2016,14(36):1-3. 被引量:4
-
9陈敏,张鹏.参芪扶正注射液在胃癌术后辅助化疗中的应用[J].中国社区医师(医学专业),2010,12(26):113-114. 被引量:3
-
10周一,黄镜,杨林,依荷芭丽·迟,屈涛,吕潇,王金万.奥沙利铂联合替吉奥在胃癌术后辅助化疗中的安全性分析[J].中华肿瘤杂志,2012,34(11):860-864. 被引量:28